AFP DEPARTMENT COLLECTION

STEPS

This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.

Mar 01, 2022 Issue
Cellulose and Citric Acid (Plenity) for Weight Management in Overweight and Obese Adults
Plenity, in combination with moderate calorie restriction, may be an effective option for adults wishing to lose weight, at least in the short term. However, as a medical device, Plenity has not been held to the same standard of testing as would be expected with medications.


Jan 01, 2022 Issue
Peanut Allergen Powder (Palforzia) for Peanut Allergy
For individuals with severe peanut allergy, peanut allergen powder may lessen the likelihood of life-threatening consequences of accidental ingestion of small amounts of peanuts. Patients must still adhere to a peanut-avoidant diet, which likely has far bigger preventive impact than peanut allergen powder therapy.


Nov 01, 2021 Issue
Tirbanibulin (Klisyri) for the Treatment of Actinic Keratosis
The cost and effectiveness profile of tirbanibulin make it a last-line option compared with current first-line therapies such as fluorouracil and imiquimod, which are less expensive and have a higher clearance rate of AK lesions. Further trials comparing the effectiveness of tirbanibulin and other AK medications are needed.


Sep 01, 2021 Issue
Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients
Although remdesivir has been shown to be safe and well tolerated, there is a lack of consistency in clinical trial results and guideline recommendations.


Jul 01, 2021 Issue
Clascoterone (Winlevi) for the Treatment of Acne
More comparative data are needed to justify the use of clascoterone over less expensive, currently available therapies for moderate to severe acne. However, systemic absorption of clascoterone is low, and it may serve as a safe alternative for patients 12 years and older who saw improvements from oral antiandrogen therapy but could not tolerate systemic adverse effects such as blood pressure changes or gynecomastia.


May 15, 2021 Issue
Lactic Acid, Citric Acid, and Potassium Bitartrate (Phexxi) Vaginal Gel for Contraception
Given its high cost, mediocre contraceptive protection, and rate of adverse effects, Phexxi may be preferred only by people desiring to avoid hormonal contraception who wish to use on-demand contraception that they control, or for whom other contraceptive options are not suited or desired.


Apr 15, 2021 Issue
Elagolix, Estradiol, and Norethindrone Kit (Oriahnn) for the Management of Heavy Menstrual Bleeding Associated with Fibroids
Oriahnn can decrease menstrual blood loss in premenopausal patients with uterine fibroids. Although it has been studied for only six months of use and may result in significant bone loss, it is labeled for up to two years of continuous therapy.


Mar 15, 2021 Issue
Bempedoic Acid (Nexletol) for the Treatment of Hyperlipidemia and Familial Hypercholesterolemia
Bempedoic acid is labeled as add-on therapy to diet and maximally tolerated statin for the treatment of familial hypercholesterolemia or atherosclerotic cardiovascular disease.


Feb 15, 2021 Issue
Lemborexant (Dayvigo) for the Treatment of Insomnia
Lemborexant (Davigo) is labeled for adults with insomnia to improve with sleep onset and maintenance.


Jan 15, 2021 Issue
Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke
Icosapent ethyl is safe, well tolerated and effective in preventing ischemic events including stroke and heart attack.


Pages: 1 2 3 4 5 6 7 8 9 10 ... 16 Next


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now